Why Apogee Therapeutics Stock Triumphed on Thursday The company aims to raise gross proceeds of roughly $300 million in a new capital-raising effort.
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out The small biotech company is looking to take on Regeneron and Sanofi's blockbuster, Dupixent.
What's going on in today's after hours session Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Let's uncover which stocks are experiencing notable gaps during today's session. Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Apogee Reverses Lower Despite Promise For Twice-Yearly Eczema Shot Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.
What's going on in today's pre-market session Wondering what's happening in Monday's pre-market session? Find an overview in this article.
Apogee Therapeutics' Eczema Drug Provides Rapid Itch Relief In Phase 2 Trial Apogee's APG777 showed a 71% drop in eczema severity and strong itch relief in a Phase 2 trial for atopic dermatitis. Part B is ongoing.
Why Is Apogee Therapeutics Stock Trading Higher On Monday? Apogee's APG808 cut key asthma biomarker FeNO by 53% at 12 weeks with no severe adverse events, showing potential for long-term maintenance dosing.
Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial will compare APG279 to Dupixent.
APGE Stock Earnings: Apogee Therapeutics Meets EPS for Q2 2024 APGE stock results show that Apogee Therapeutics met analyst estimates for earnings per share the second quarter of 2024.
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details 10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.
